ReviewBiopolymers2026
From Synthesis to Therapeutics: Bioactive-Coated Zein Nanoparticles in Drug Delivery.
Review in Biopolymers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Polymeric zein nanoparticles (ZNP), derived from corn protein, are biodegradable drug carriers with high stability and low synthesis costs. Their amphiphilic nature allows efficient encapsulation of both hydrophilic and lipophilic drugs, making them promising for drug delivery. However, their instability under physiological pH can limit therapeutic efficacy, necessitating protective coatings for improved absorption. This review discusses synthesis methods, coating materials, and biological activities of bioactive-coated ZNP. We found that the antisolvent method is the most commonly used due to its simplicity and cost-effectiveness, while chitosan is the preferred coating material. ZNP exhibit antioxidant, anticancer, anesthetic, antidiabetic, hypoglycemic, and immunogenic properties, as demonstrated in both in vitro and in vivo studies. Their ability to enhance bioavailability, reduce toxicity, and enable targeted drug delivery highlights their potential in nanomedicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.